All In MedTech

Device Trial Radar · NCT03421626

Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)

Clinical Evaluation of the Xpert BCR-ABL Ultra Assay on the GeneXpert Instrument Systems

Last checked: Nov 20, 2026Latest source record: Apr 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

266

Actual

Start

Nov 8, 2017

Primary completion

Aug 20, 2018

Study completion Aug 20, 2018

Sponsor

Lead sponsor
CepheidNot on our public-company list
Sponsor type
Industry
First posted
Feb 5, 2018

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to establish the performance of an assay that detects mRNA transcript levels in patients diagnosed with CML. The study is conducted at locations within the United States. Testing is performed on peripheral blood specimens provided by eligible enrolled patients. Results from this study will not be used for patient management decisions.

Conditions

  • Leukemia, Myelogenous, Chronic

Interventions

  • Xpert BCR-ABL UltraDevice

    Semi-quantitation of BCR-ABL transcript in patients that have been previously diagnosed with CML

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Method comparison to an on-market molecular diagnostic assayTime frame: Baseline = testing upon enrollment

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Broward Oncology Associates

    Fort Lauderdale, Florida

  • St. Alphonsus Regional Medical Center

    Boise, Idaho

  • WJB Dorn VA Medical Center

    Columbia, South Carolina

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.